What is the recommended dosage of tropical Pepsi in the treatment of cannabinoid hyperemesis syndrome?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 2, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

There is No Recommended Dosage for "Tropical Pepsi" in Cannabinoid Hyperemesis Syndrome

"Tropical Pepsi" is not a recognized or evidence-based treatment for cannabinoid hyperemesis syndrome (CHS), and no medical literature supports its use. This appears to be either a misunderstanding or confusion with actual therapeutic interventions for CHS.

Evidence-Based Treatments for CHS

Definitive Treatment

  • Cannabis cessation is the only definitive cure for CHS and should be the primary therapeutic goal 1, 2.
  • Symptoms resolve after abstinence for at least 6 months or duration equal to 3 typical vomiting cycles 1, 2.

Acute Management in the Emergency Department

First-line pharmacological options:

  • Haloperidol 5 mg IV has the strongest evidence for acute symptom relief and is superior to conventional antiemetics like ondansetron 3, 4.
  • Droperidol (another butyrophenone) is also effective 1.
  • Topical capsaicin 0.1% cream applied to the abdomen activates TRPV1 receptors and provides symptom relief 1, 2, 3.

Adjunctive therapies:

  • Lorazepam 2 mg IV combined with haloperidol 5 mg IV has shown excellent results in case series 4.
  • Benzodiazepines alone may provide relief by decreasing CB1 receptor activation in the frontal cortex and reducing anticipation of nausea 5.

Therapies with limited efficacy:

  • Ondansetron and metoclopramide are generally poorly effective in CHS compared to their use in other conditions 1, 3.
  • Avoid opioids as they worsen nausea and carry high addiction risk 1, 2, 3.

Long-Term Management

Pharmacological approach:

  • Amitriptyline is the mainstay of long-term therapy: Start at 25 mg at bedtime, titrate weekly by 25 mg increments to reach the minimal effective dose of 75-100 mg 1, 2.
  • Continue topical capsaicin 0.1% with close monitoring of efficacy and adverse effects 1.

Non-pharmacological essentials:

  • Cannabis cessation counseling is mandatory 1, 2.
  • Psychological support for comorbid anxiety and depression 2.
  • Consider psychiatry co-management for treatment-resistant cases 2.

Common Pitfalls to Avoid

  • Do not rely on conventional antiemetics (ondansetron, metoclopramide) as primary therapy—they are largely ineffective in CHS 1, 3.
  • Do not prescribe opioids for symptom management as they exacerbate nausea 1, 2, 3.
  • Do not miss the diagnosis by failing to ask about cannabis use patterns (>4 times weekly for >1 year) and characteristic hot shower relief 1, 2.
  • Rule out life-threatening conditions first including acute abdomen, bowel obstruction, mesenteric ischemia, pancreatitis, and myocardial infarction before attributing symptoms to CHS 1.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Cannabis Hyperemesis Syndrome (CHS)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Managing cannabinoid hyperemesis syndrome in adult patients in the emergency department.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2025

Research

Resolution of Cannabinoid Hyperemesis Syndrome with Benzodiazepines: A Case Series.

The Israel Medical Association journal : IMAJ, 2019

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.